Sumatriptan SUN

Quick links to important sections

Sumatriptan SUN

Method of action: Analgesic, Antimigraine, Serotonergic

Treatment option: Headache, Cluster Headache, Migraine

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sumatriptan SUN

Property Description
Active ingredient Sumatriptan Succinate
Form Tablet, Solution for Injection, Nasal Spray
Pharmacological class Triptan / Selective Serotonin Receptor Agonist
Common use Acute treatment of severe headache episodes
Origin Synthetic compound (Indole acetic acid analogue)

The Identity and Classification of Sumatriptan SUN

Sumatriptan SUN is a single-ingredient, prescription-only medicinal agent primarily used for the acute treatment of headache attacks classified as migraines or cluster headaches. It belongs to the Triptan class of medications, which are scientifically termed Selective Serotonin 5-HT1B/5-HT1D Receptor Agonists. This classification identifies the drug as a specialized Antimigraine Agent designed to interrupt the progression of a headache after its onset, rather than serving a preventative role. The compound is clinically recognized for its focused action against neurovascular pain mechanisms inherent to these headache types.

Composition, Origin, and Available Forms

The key active substance in the medicine is the synthetic compound Sumatriptan, which is formulated and administered as the readily absorbable Succinate salt. This compound is a monotherapy product, being composed of only the single active ingredient. Its chemical structure, an indole acetic acid analogue, allows it to effectively interact with the body's natural serotonergic system. Sumatriptan SUN is prepared in various pharmaceutical forms, including the standard oral tablet, a sterile solution for injection for subcutaneous administration, and a liquid nasal spray for intranasal delivery, confirming its various routes of administration.

How Sumatriptan SUN Achieves Its Therapeutic Role

Sumatriptan functions by selectively binding to specific serotonin receptors located primarily on blood vessels and nerve endings in the head. This targeted action causes cranial vasoconstriction (the narrowing of certain dilated vessels) and facilitates nerve signal quieting by inhibiting the release of certain pain-inducing neuropeptides. The overall goal of this specialized mechanism is to rapidly interrupt the underlying painful cascade of an acute headache episode, explaining why the medicine works to stop the pain and associated symptoms once an attack has started.

Regulatory References

  1. U.S. National Library of Medicine
  2. European Medicines Agency (EMA) Public Assessment Report for Sumatriptan SUN

What side effects are possible with Sumatriptan SUN?

Possible Side Effects and Safety Information

The safety profile of Sumatriptan SUN is characterized by adverse reactions classified by frequency and the body system affected, consistent with official regulatory documents. Many reported effects are generally transient and often occur soon after administration.


Frequency-Classified Adverse Reactions

The most frequently documented side effects are categorized as Common (affecting 1 to 10 out of 100 people) and typically involve the nervous and vascular systems:

  • Nervous System: Dizziness, somnolence, and sensory disturbances such as tingling, sensations of heat, or cold.
  • Vascular/General: Transient increases in blood pressure, flushing, and characteristic sensations of pressure, heaviness, or tightness in the chest, throat, or neck area. Nausea, vomiting, and feelings of weakness or fatigue are also common.

Serious Adverse Reactions and Safety Constraints

The official label documents rare, but clinically significant, Serious Adverse Reactions. These include life-threatening events such as Serotonin Syndrome, serious allergic reactions (anaphylaxis), and major Cardiovascular/Cerebrovascular ischemic events, including myocardial infarction (heart attack) and stroke. Convulsions (seizures) have also been reported.

Use is subject to specific safety restrictions. The medicine is contraindicated in individuals with a history of ischemic heart disease, uncontrolled hypertension, or other peripheral vascular diseases. It is not recommended for use in older adults (ages 65 and up) or those with severe hepatic impairment. Furthermore, long-term, frequent use of acute migraine treatments is associated with the risk of Medication-Overuse Headache.

Overdose and Emergency Response

The official regulatory documentation mandates that immediate medical attention must be sought if an overdose of Sumatriptan SUN is suspected. Overdose is officially described with the potential for severe or life-threatening manifestations, primarily affecting the central nervous and cardiovascular systems.

Documented Overdose Manifestations

System Affected Officially Described Signs
Central Nervous System Seizures; symptoms of Serotonin Syndrome (altered mental status, neuromuscular abnormalities, and autonomic instability).
Cardiovascular System Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation; severe coronary artery vasospasm.
Gastrointestinal Vomiting (reported with high doses).

Emergency Management and Monitoring

Official prescribing information confirms that no specific antidote is known for Sumatriptan. Treatment consists exclusively of symptomatic and supportive therapy.

Due to the risk of documented serious complications, regulators require that a patient suspected of overdose be held for extended observation. Mandatory hospital monitoring for a minimum of 10 hours is specified. Continuous ECG monitoring is necessary, especially for patients at risk of cardiovascular complications. Any suspected overdose requires immediate contact with emergency medical services.

Therapeutic Uses of Sumatriptan SUN

Quick Facts: Sumatriptan SUN Therapeutic Uses

  • Acute Migraine Treatment: Used for the acute relief of migraine attacks, with or without aura.
  • Cluster Headache Management: Indicated for the acute treatment of cluster headache attacks.
  • Mechanism of Action: Functions as a selective serotonin receptor agonist to provide relief from pain.

Therapeutic Overview of Sumatriptan SUN

Sumatriptan SUN is a prescription medication designated for the acute treatment of certain severe headaches. Its primary medical use is to provide relief from migraine attacks, which can occur with or without an aura. It is important to note that this medication is not intended for the prevention of migraine attacks, but rather for managing the symptoms once an attack has started.

In addition to migraines, Sumatriptan SUN is also indicated for the acute treatment of cluster headache attacks. This medication should only be used where a clear diagnosis of either condition has been established by a healthcare professional. The acute use of Sumatriptan SUN aims to manage the symptoms of the attack, allowing the patient to return to normal activity more quickly.

Regulatory References

  1. Public Assessment Report for Sumatriptan SUN

Eligibility and Restrictions for Use

This section outlines the official population eligibility and exclusion rules for Sumatriptan SUN, as documented in regulatory prescribing information.

Contraindicated Populations

Use of this medicine is absolutely prohibited (contraindicated) for patients with a history or current signs of:

  • Ischaemic Heart Disease (IHD): Including angina, myocardial infarction, or documented silent ischemia.
  • Cerebrovascular Disease: Including history of stroke (CVA) or transient ischaemic attack (TIA).
  • Uncontrolled Hypertension, Severe Hepatic Impairment, or a history of specific atypical migraines like hemiplegic or basilar migraine.
  • Recent Drug Use: Use within two weeks of stopping a Monoamine Oxidase-A (MAO-A) inhibitor or within 24 hours of using another triptan or ergotamine-containing medication.

Age-Related Eligibility

Age Group Regulatory Status
Adults (18-65 years) Approved for use.
Children/Adolescents (Under 18) Not Recommended; safety/efficacy not established.
Older Adults (Over 65) Not Recommended; clinical experience is limited.

Specific Limitations

Patients with cardiovascular risk factors (e.g., smokers, hypertension) require a prior cardiovascular evaluation before use. For pregnancy, treatment should only proceed if the expected benefit justifies the potential risk. Breastfeeding mothers are advised to avoid nursing for 12 hours after treatment, as the substance is secreted into breast milk.

What should I know about interactions with other medicines?

Documented Interaction Patterns and Regulatory Restrictions

Official regulatory information for Sumatriptan SUN is characterized by strict prohibitions on co-administration with substances that amplify its primary actions or impede its clearance.

Classification Interacting Agents Regulatory Constraint
Contraindicated Combination Monoamine Oxidase-A (MAO-A) Inhibitors Use is prohibited concurrently or within two weeks of stopping MAOI therapy. MAO-A inhibition significantly reduces sumatriptan clearance, increasing systemic exposure.
Contraindicated Combination Ergotamine-containing Medicines / Ergot Derivatives; Other Triptans Use is prohibited within 24 hours of taking Sumatriptan SUN. The combination risks additive vasoconstrictive effects, potentially leading to prolonged vasospasm.
Significant Interaction Risk Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) The combination carries an officially recognized risk of Serotonin Syndrome due to additive effects on serotonergic activity.

Sumatriptan's official interaction profile includes constraints for patients with severe hepatic impairment, as this condition impairs the presystemic clearance necessary for orally administered sumatriptan. Pharmacokinetic studies documented by regulatory bodies indicate that the bioavailability of the oral tablet formulation is not significantly affected by co-administration with food or alcohol.

Mechanism of Action

How Sumatriptan SUN Works: The Mechanism of Action

Targeted Action on Serotonin Receptors

Sumatriptan SUN functions as a highly selective agonist on two primary receptor subtypes: the 5- HT1 B and 5- HT1 D serotonin receptors. This engagement is targeted within the trigeminovascular system and initiates a focused cellular response. The drug's mechanism is driven purely by direct receptor activation rather than enzyme inhibition, guiding the system toward a corrective physiological state.


Dual Modulation of Vasculature and Neurotransmitters

The activation of these receptors leads to a dual corrective mechanism. Stimulation of the 5- HT1 B receptors on cranial blood vessels induces selective vasoconstriction, counteracting the pathological dilation. Concurrently, activation of the 5- HT1 D receptors on trigeminal nerve endings causes presynaptic inhibition, inhibiting the release of pro-inflammatory mediators such as Calcitonin Gene-Related Peptide (CGRP).


Interruption of the Neurovascular Cascade

By addressing both the excessive vascular signaling and the nerve-mediated inflammation simultaneously, this combined neurovascular action intervenes in the progression of the acute pathology. This process effectively limits the nociceptive input traveling from the meninges to the brain's pain centers, leading to the termination of the signaling cascade that drives the acute episode. This mechanism is defined as an acute reversal process and is therefore not applicable in a preventative setting.

Dosage and Administration Information

Sumatriptan tablets are indicated for the acute treatment of migraine attacks, with or without aura, in adults. It is not intended for the prevention of migraines or the treatment of cluster headaches.

Administration Guidelines

Take your dose of Sumatriptan SUN as soon as the migraine headache begins, but not during the aura phase that precedes the pain. The tablet should be swallowed whole with water, and should not be crushed or chewed. You may take the tablet with or without food.

Action Recommended Dose Maximum Dose in 24 Hours
Initial Single Dose 25 mg, 50 mg, or 100 mg 200 mg
Second Dose (If Migraine Returns) The same initial dose

Important Dosing Instructions

  • No Initial Response: If the first tablet does not relieve your migraine symptoms, do not take a second dose for the same attack. The attack may be treated with non-triptan pain relievers, and Sumatriptan may be used for a subsequent migraine attack.
  • Recurrent Symptoms: If your migraine symptoms partially improve but then return after an initial response, a second dose may be administered. This second dose must be taken at least two hours after the first dose.
  • Do not exceed the maximum daily dose of 200 mg within a 24-hour period.
  • Hepatic Impairment: For patients with mild to moderate hepatic impairment, the maximum single dose should not exceed 50 mg.

Consult your healthcare provider if your headaches become more frequent or if you need to use Sumatriptan for more than four headaches in a 30-day period, as this may indicate a risk of medication-overuse headache.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sumatriptan SUN

Evidence for Acute Migraine Attack in Adults

Research on the acute treatment of migraine in adults is primarily based on Randomized Controlled Trials (RCTs) and subsequent Meta-analyses. Studies focused on defining outcomes related to physical discomfort by measuring the proportion of participants who achieved a pain-free state within two hours post-dose, along with measurements related to sustained pain freedom for 24 hours. The research also monitored changes in associated symptoms like nausea. This evidence base for adults is generally considered to have a High level of consistency.

Evidence for Acute Cluster Headache Attack in Adults

For acute cluster headache episodes, research involved Randomized Controlled Trials designed to monitor responses over very short time intervals (15 and 30 minutes). Studies explored patient-reported outcomes describing perceived discomfort and the consistency of these responses across sequential attacks. This body of research, particularly for the subcutaneous route, was also assigned a High level of supporting evidence.

Evidence in Special Age Groups and Research Gaps

Research has explored the use of the medicine in adolescents (12-17 years old) and children (8-11 years old). While controlled trials were conducted, the consistency of findings in these younger age groups has been assessed as Moderate to Low. Study outcomes were often mixed, with trial results sometimes reporting measurements where the primary endpoint was not met.

The full scope of long-term effects is not yet fully established. A key gap is the need for more established data related to the effects of the medicine when was studied for use in treating more than four headaches in a single month. Overall, research provides context for group patterns observed, but the results apply only to the populations studied and do not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Sumatriptan SUN (FAQ)


Q: How quickly does Sumatriptan SUN typically start to work after taking it?

A: Studies on the efficacy of sumatriptan tablets often measure relief by the proportion of patients who achieve a pain-free state within two hours post-dose. While some patients may notice relief sooner, this two-hour mark is the typical measurement used in clinical trials documented in official product information.


Q: What should I do if Sumatriptan SUN doesn't work for my migraine?

A: If the first dose of Sumatriptan SUN does not relieve the migraine symptoms, official guidelines state a second dose should not be taken for the same attack. The attack may instead be treated with non-triptan pain relievers.


Q: What are the concerns about using Sumatriptan SUN in older adults (seniors)?

A: Official product information states that Sumatriptan is not generally recommended for patients over 65 years of age. This is mainly because clinical experience in this age group is limited, and older adults are more likely to have underlying cardiovascular conditions, which are a major safety concern.


Q: Can Sumatriptan SUN be used by teenagers or is it only for adults?

A: Sumatriptan is not recommended for use in children and adolescents under 18 years old. According to official regulatory documents, this is because the safety and effectiveness of the medicine have not been clearly established in these younger age groups.


Q: Is it necessary to take Sumatriptan SUN at the very start of a migraine aura?

A: No. Sumatriptan SUN is indicated for the acute treatment of the migraine headache phase, not during the aura phase that precedes the pain. The medicine should generally be taken as soon as the migraine headache itself begins.


Q: Can I take a second dose of Sumatriptan SUN if the first one wore off too quickly?

A: If migraine symptoms partially improve but then return, official dosing instructions permit a second dose. This second dose must be taken at least two hours after the first dose, according to regulatory guidelines.


Q: What is the longest a single dose of Sumatriptan SUN is expected to last?

A: Clinical trials often measure the medicine's effectiveness by determining the proportion of patients who achieve sustained pain freedom for 24 hours after dosing. This 24-hour period is the benchmark used in research to evaluate sustained relief.


Q: Does Sumatriptan SUN help with the nausea and light sensitivity that comes with migraines?

A: Clinical studies and regulatory reviews include monitoring the relief of migraine-associated symptoms, such as nausea, alongside the treatment of pain. The medicine is intended to interrupt the painful signaling cascade of an acute migraine attack.


Q: Is Sumatriptan SUN effective for menstrual migraines specifically?

A: The official indication for Sumatriptan is for the acute treatment of migraine attacks with or without aura in adults. The regulatory indication does not impose restrictions based on the migraine trigger, meaning it can be used for acute menstrual migraines.


Q: What research is available about the long-term effects of using Sumatriptan SUN?

A: Official safety information notes that the full scope of the medicine's long-term effects is not yet fully established. However, frequent use of acute migraine treatments is clearly associated with the risk of developing a Medication-Overuse Headache, a key long-term concern addressed in regulatory documents.


Q: Is it safe to drink coffee after taking Sumatriptan SUN?

A: Regulatory documents do not list a direct drug interaction between sumatriptan and caffeine. While the drug's label does not list caffeine as a direct drug interaction, patients may wish to consult their prescribing information about diet.


Q: Is the injection form of Sumatriptan SUN absorbed faster than the tablet?

A: Yes, regulatory documents note that Sumatriptan is available in various forms, including oral, nasal, and subcutaneous (injection). The subcutaneous injection route is generally associated with the most rapid onset of action compared to the tablet or nasal spray forms.


Q: Why do some people experience a metallic taste after using the nasal spray formulation of Sumatriptan?

A: The nasal spray formulation of Sumatriptan has specific adverse reactions related to its route of administration. These include localized effects like taste disturbances and nasal or throat discomfort, which are documented in the official product information.


Q: Can Sumatriptan SUN be used during pregnancy or breastfeeding?

A: Official guidance states that use during pregnancy is recommended only if the potential benefit is considered to justify the potential risk. For breastfeeding, official guidelines recommend avoiding nursing for 12 hours after treatment, as the substance is known to be secreted into breast milk.


Q: What happens if I accidentally take too much Sumatriptan SUN?

A: An accidental overdose may lead to serious adverse reactions. Regulatory documents list possible effects that can include seizures, tremor, or cardiovascular events. It is necessary to seek emergency medical attention in the event of an overdose.


Q: Does the efficacy of Sumatriptan SUN change based on age or gender?

A: Official pharmacokinetic studies, which track how the body processes the drug, found no significant differences in how Sumatriptan is cleared or absorbed based on adult gender or for different adult age groups.


Q: Why does Sumatriptan SUN sometimes cause neck pain or stiffness?

A: Neck pain, stiffness, and sensations of pressure, heaviness, or tightness in the neck and chest are documented as Common adverse reactions. These effects are usually transient (short-lived) and occur soon after administration.


Q: Is it true that Sumatriptan SUN can worsen anxiety or cause mood changes?

A: Official regulatory labels list mood changes, agitation, and anxiety as adverse reactions reported in clinical trials or through post-marketing experience. The serious risk of Serotonin Syndrome is also associated with symptoms such as confusion and agitation.


Q: Are there any specific foods that should be avoided when using Sumatriptan SUN?

A: The official product information indicates that the absorption of the oral tablet formulation is not significantly affected by co-administration with food. Patients are encouraged to review potential food triggers with a healthcare professional.


Q: Are there different brands of Sumatriptan and are they all the same as SUN?

A: The drug name Sumatriptan is the active ingredient and is available under various brand names, including generics. All products containing the same active ingredient are required to meet the same official regulatory standards for quality, strength, and purity.


Q: Can Sumatriptan SUN cause a temporary increase in blood pressure?

A: Yes, transient increases in blood pressure are documented as a common adverse reaction associated with the use of Sumatriptan. For this reason, the drug is contraindicated in patients with uncontrolled hypertension.


Q: Is it normal to feel a 'rush' or feeling of warmth after taking it?

A: Yes, official regulatory documents classify sensations of heat or flushing as common adverse reactions that have been documented in clinical trials.


Q: Why do people sometimes say they feel 'spaced out' on Sumatriptan SUN?

A: This feeling may relate to the documented common nervous system side effects of the medicine. Official safety information lists dizziness and somnolence (drowsiness) as frequently reported adverse reactions.


Q: Can I use Sumatriptan SUN if I have a history of kidney problems?

A: Regulatory documents state that the effect of kidney impairment on how the body processes Sumatriptan has not been thoroughly examined. However, little clinical effect would be expected since the drug is largely metabolized to an inactive substance.


Q: What should I do if my migraine symptoms partially improve but then return after an initial response?

A: If migraine symptoms partially improve but then return, official dosing guidelines permit a second dose. This second dose must be taken at least two hours after the first dose.

How should Sumatriptan SUN be stored and disposed of?

The storage and disposal of Sumatriptan SUN injection are defined by official regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Item Requirement
Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F); store away from heat.
Light Protection Must be stored in the original package to protect from light.
Stability The single-dose injection must be discarded immediately after use; do not keep unused portions.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired medicine and waste material in accordance with local requirements and pharmaceutical waste procedures. The product should not be disposed of via wastewater or routine household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sumatriptan SUN found in:

A-Z Index: